Is Replimune Group, Inc. (REPL) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 11.4% / 30% | 72.6% / 30% | 0.6% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 11.4% / 33% | 72.6% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 13.8% / 33% | 87.8% / 33% | 0.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 11.4% / 33% | 72.6% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 13.8% / 33% | 87.8% / 33% | 0.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -90.9% | |
| Return on Assets (ROA) | -43.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$192M |
| Free Cash Flow | -$199M |
| Total Debt | $76M |
| Debt-to-Equity | 36.3 |
| Current Ratio | 5.6 |
| Total Assets | $551M |
Price & Trading
| Last Close | $7.54 |
| 50-Day MA | $7.53 |
| 200-Day MA | $7.64 |
| Avg Volume | 1.4M |
| Beta | 0.8 |
|
52-Week Range
$2.68
| |
About Replimune Group, Inc. (REPL)
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Replimune Group, Inc. (REPL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Replimune Group, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Replimune Group, Inc.'s debt ratio?
Replimune Group, Inc.'s debt ratio is 11.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.8%.
What are Replimune Group, Inc.'s key financial metrics?
Replimune Group, Inc. has a market capitalization of $596M. Return on equity stands at -90.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.